The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells

Chun-Yu Liu1,2,3, Tzu-Ting Huang1,2, Pei-Yi Chu4,5, Chun-Teng Huang3,6, Chia-Han Lee2, Wan-Lun Wang2, Ka-Yi Lau2, Wen-Chun Tsai2, Tzu-I Chao7, Jung-Chen Su8, Ming-Huang Chen2,3, Chung-Wai Shiau8, Ling-Ming Tseng1,3,9 and Kuen-Feng Chen10,11

Triple-negative breast cancer (TNBC) remains difficult to treat and urgently needs new therapeutic options. Nintedanib, a multikinase inhibitor, has exhibited efficacy in early clinical trials for HER2-negative breast cancer. In this study, we examined a new molecular mechanism of nintedanib in TNBC. The results demonstrated that nintedanib enhanced TNBC cell apoptosis, which was accompanied by a reduction of p-STAT3 and its downstream proteins. STAT3 overexpression suppressed nintedanib-mediated apoptosis and further increased the activity of purified SHP-1 protein. Moreover, treatment with either a specific inhibitor of SHP-1 or SHP-1-targeted siRNA reduced the apoptotic effects of nintedanib, which validates the role of SHP-1 in nintedanib-mediated apoptosis. Furthermore, nintedanib-induced apoptosis was attenuated in TNBC cells expressing SHP-1 mutants with constantly open conformations, suggesting that the autoinhibitory mechanism of SHP-1 attenuated the effects of nintedanib. Importantly, nintedanib significantly inhibited tumor growth via the SHP-1/p-STAT3 pathway. Clinically, SHP-1 levels were downregulated, whereas p-STAT3 was upregulated in tumor tissues, and SHP-1 transcripts were associated with improved disease-free survival in TNBC patients. Our findings revealed that nintedanib induces TNBC apoptosis by acting as a SHP-1 agonist, suggesting that targeting STAT3 by enhancing SHP-1 expression could be a viable therapeutic strategy against TNBC.

Experimental & Molecular Medicine (2017) 49, e366; doi:10.1038/emm.2017.114; published online 11 August 2017

INTRODUCTION
Triple-negative breast cancer (TNBC) is distinguished by the paradox of a favorable chemotherapeutic response but higher rates of early recurrence and worse outcomes compared to non-TNBC as well as its heterogeneous molecular profiling.1,2 Currently, there is no approved targeted therapy for TNBC despite the suggestion of various strategies targeting the heterogeneous molecular pathways or subtypes, such as PARP inhibitors for BRCA-deficient subtypes and anti-androgen molecules for androgen receptor-expressing subtypes.1,2 The identification of novel therapeutic targets and the development of new agents for TNBC remains a challenging task and represents an unmet need.

Src homology region 2 domain containing phosphatase 1 (SHP-1) is a non-receptor protein tyrosine phosphatase (PTP) and a tumor suppressor gene in different cancer types.3 SHP-1 has an N-terminal Src homology-2 (N-SH2) domain, a C-terminal catalytic PTP domain, and a C-terminal SH2 domain (C-SH2).3,4 SHP-1 has an autoinhibitory conformation through the interaction between its N-SH2 domain and its C terminus.5 SHP-1 participates in cell growth and survival signaling by...
Nintedanib induces apoptosis via activating SHP-1
C Y Liu et al

dephosphorylating several crucial kinases such as BCR-ABL, insulin receptor, lymphocyte-specific protein tyrosine kinase, phosphoinositide 3-kinase as well as affecting the JAK/STAT pathway. Signal transducer and activator of transcription 3 (STAT3) regulates the proliferation, metastasis, angiogenesis and drug resistance of cancer cells. Constitutive STAT3 activity has been reported in almost 70% of breast cancers, particularly in TNBC. In addition, abnormally activated STAT3 increases invasion and metastasis in TNBC. As a result, targeting STAT3 might be a potential therapeutic approach for treating TNBC.

Nintedanib is a multитargeted angiokinase inhibitor against many growth factor receptors, including PDGFR, FGFR, VEGFR, as well as the proto-oncogenes RET, FTL3 and Src, with anti-angiogenic activity. This novel angiokinase inhibitor is currently in phase II–III clinical trials for the treatment of advanced ovarian cancer (NCT01610869), non-small-cell lung cancer (NCT00806819) and metastatic colorectal cancer (NCT02393755). In breast cancer research, the combination of nintedanib with paclitaxel promoted tumor remission in 50% of patients with early-stage HER-2-negative breast cancer. Despite its promising multitargeted angiokinase inhibitor activity, the molecular mechanism of the antitumor effect of nintedanib is poorly understood.

Therefore, we investigated the molecular mechanisms by which nintedanib enhances apoptosis to clarify the role of angiokinase inhibition in its anti-proliferative effects against TNBC. Nintedanib significantly inhibited tumor growth in a TNBC-bearing animal model via the SHP-1/p-STAT3 pathway.

MATERIALS AND METHODS

Cell culture and western blotting
MDA-MB-231, MDA-MB-468 and HCC-1395 cell lines were obtained from the ATCC (American Type Culture Collection, Rockville, MD, USA) and maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, HyClone, Thermo Scientific, Waltham, MA, USA). Cell lysates treated with nintedanib were prepared and analyzed by western blot as previously reported. Antibodies targeting p-JAK2 (Tyr1007/1008), JAK2, p-SRC (Tyr416), SRC, p-STAT3 (Tyr705), STAT3, survivin, poly (ADP-ribose) polymerase (PARP) and cleaved caspase 3 were purchased from Cell Signaling (Danvers, MA, USA). SHP-1, cyclin D1 and Mcl-1 antibodies were purchased from Abcam (Cambridge, MA, USA).

Cell cycle distribution and apoptosis assay
Cells were arrested at G0/G1 phase by serum starvation for 48 h in medium containing 0.5% FBS. Then, the synchronized cells were given fresh medium containing 10% FBS for 16 h to allow reentry into the cell cycle, and the cells were then incubated in the presence or absence of nintedanib. Cellular DNA content that represented the cell cycle phase (sub-G1, G0/G1, S or G2/M) was detected by flow cytometry via propidium iodide staining. For the apoptosis assay, cells were incubated in the presence or absence of nintedanib for 48 h. Then, the cells were washed with cold PBS, resuspended in annexin V binding buffer (BD Pharmingen, San Diego, CA, USA), and treated with APC-conjugated annexin V (BD Pharmingen) and propidium iodide (Sigma, St Louis, MO, USA). The apoptotic cells were detected by flow cytometry.

Gene knockdown and SHP-1 phosphatase activity
siRNAs targeting SHP-1 and scrambled control siRNAs were purchased from Dharmaco (Thermo Scientific, Chicago, IL, USA). Cells were transfected with siRNAs using Lipofectamine 2000 (Invitrogen Life Technologies, Rockville, MD, USA) to knock down gene expression. For SHP-1 activity assay, a RediPlate 96 EnzChek Tyrosine Phosphatase Assay Kit (Molecular Probes, Carlsbad, CA, USA) was used following the manufacturer’s instructions.

Xenograft tumor growth
Female BALB/c nu/nu mice (5–7 weeks of age) were obtained from the National Laboratory Animal Center (Taipei, Taiwan, Republic of China). All animal experiments performed in this study were conducted in accordance using protocols approved by the Institutional Animal Care and Use Committee at Taipei Veterans General Hospital. Each mouse was subcutaneously injected in the dorsal flank with 5 × 10^6 cells as previously described. The volume of xenografted tumors was calculated using the standard formula width^2 × length × 0.52. Based on the previous studies, effective and well-tolerated doses of nintedanib in mice were calculated in the range of 30–100 mg kg^-1. A dose of 30 mg kg^-1 per day was considered close enough to the maximum tolerated dose in mice without eliciting an obvious effect on the phenotype; therefore, we chose this dose for the animal studies. When tumors reached 100–200 mm^3 in size, mice were orally administered nintedanib (30 mg kg^-1) three times a week. Control mice received vehicle. All the mice were killed on day 33, and the xenografted tumors were harvested and assayed for subsequent experiments.

Immunohistochemical staining
In brief, 4-μm-thick paraffin-embedded tissue sections from patients with TNBC were placed on poly-l-lysine-coated slides and prepared and stained as previously described. The expression levels of p-STAT3 and SHP-1 were semiquantitatively assessed based on the staining intensity by a board-certified pathologist.

Surgical samples
A total of 74 patients with TNBC who underwent surgical treatment at the Department of Surgery at Taipei Veterans General Hospital were enrolled in this study. Informed consent was obtained from all the patients, and this study was approved by the Institutional Review Board in Taipei Veterans General Hospital prior to initiation.

In silico survival analysis using a publicly available database
A Kaplan–Meier survival analysis of patients with breast cancer based on SHP-1 (gene name PTEN6, Affymetrix probe ID 206687, Budapest, Hungary) mRNA expression was obtained from the Kaplan–Meier plotter online database (http://kmplot.com/analysis/index). Relapse-free survival curves were plotted for patients with TNBC (n = 249) and all breast cancer subtypes (n = 3554). An autoselected optimal cutoff was chosen in the analysis.

Statistical analysis
Data analysis was based on nonparametric tests, and the differences were considered statistically significant if P < 0.05. The results were presented as the mean ± s.d. or s.e. For survival analysis, disease-free survival curves of patients were generated by the Kaplan–Meier method and compared using a log-rank test. All statistical analyses were conducted using SPSS for Windows software, version 12.0 (SPSS, Chicago, IL, USA).
RESULTS
Nintedanib exerts an anti-proliferative effect on TNBC cell lines
To examine the anti-tumor ability of nintedanib on human TNBC cells, we first tested the effects of nintedanib on cell growth in three TNBC cell lines: MDA-MB-231, MDA-MB-468 and HCC-1395. As shown in Figure 1a, nintedanib treatment inhibited cell proliferation in a dose-dependent manner. Inhibition of cell proliferation could be the result of apoptosis induction, cell cycle arrest and/or growth inhibition. We therefore investigated whether nintedanib could induce apoptosis or affect the cell cycle distribution in TNBC cells. The results indicated that nintedanib significantly increased the differential apoptotic effects (Figure 1b) in these TNBC cells in a dose-dependent manner. Nintedanib treatment had a mild effect on the population size in the G0/G1, S and G2/M phases but significantly increased the subG1 cell population (Supplementary Figure 1). To further test the cytotoxic effect of nintedanib on normal MCF-10A human breast epithelial cells, the MTT assay and flow cytometry analysis were performed. Nintedanib exerted milder anti-proliferative activity and a more minimal apoptosis-inducing effect on MCF-10A cells compared to those of the TNBC cell lines (Figure 1b and Supplementary Figure 2, lower panel). Our results showed that nintedanib exerted more cytotoxic effects on TNBC cells than on normal breast MCF-10A cells.

Nintedanib enhances cell apoptosis by decreasing p-STAT3 levels in TNBC cells
Given the potential anti-tumor activity of nintedanib, we next focused on nintedanib in TNBC treatment and examined the underlying molecular mechanisms of its function. The results showed that nintedanib inhibited the expression levels of activated STAT3 (p-STAT3) and its downstream pro-proliferative molecules Mcl-1, cyclin D1 and survivin at the indicated doses (Figure 2a). Importantly, PARP is an important marker of caspase 3-mediated apoptosis and was activated in cells treated with nintedanib (Figure 2a). Moreover, nintedanib induced considerable time-dependent apoptosis and reduction of p-STAT3 levels (Figure 2b). We also examined the effects of nintedanib on STAT3 phosphorylation in the cytoplasm and nucleus. As shown in Supplementary Figure 3, nintedanib treatment had no obvious effect on total STAT3 levels but significantly decreased the phosphorylation of STAT3 in both the cytoplasm and nucleus. These results suggested that STAT3 inhibition may be the major mechanism of nintedanib-induced apoptosis in TNBC. To further validate the role of STAT3, we transiently transfected MDA-MB-231 cells with a STAT3 overexpression vector to determine the molecular changes induced by nintedanib. Ectopic expression of STAT3 increased p-STAT3 protein levels and decreased nintedanib-mediated apoptosis, suggesting that activated STAT3 signaling counteracts the anti-tumor activity of nintedanib (Figure 3a).

Figure 1 Nintedanib exerts anti-proliferative activity in TNBC cell lines. (a) Dose-dependent effects of nintedanib on cell viability in MDA-MB-231 (left), MDA-MB-468 (middle) and HCC-1395 (right) cells. Cells treated with nintedanib at the indicated doses for 48 h were measured by an MTT assay. (b) Dose-dependent effects of nintedanib on apoptosis in MDA-MB-231 (left), MDA-MB-468 (middle) and HCC-1395 (right) cells. Cells were treated with nintedanib at the indicated doses and times. Apoptotic cells were analyzed by flow cytometry, and the means of at least three independent experiments performed in triplicate are shown. The data are shown as the mean ± s.d.
Nintedanib targets SHP-1 in TNBC cells
According to previous studies, SHP-1 serves as a crucial negative regulator in STAT3 signaling; thus, we determined whether SHP-1 is involved in nintedanib-induced STAT3 suppression. We used a specific SHP-1 inhibitor (PTP III) as well as knocked down SHP-1 via transient transfection of SHP-1-targeted siRNAs to analyze the effect of nintedanib on TNBC cells. Blocking SHP-1 via either PTP III or siRNA

Figure 2 Nintedanib induces cell apoptosis by inhibiting STAT3 signaling. (a) Dose-dependent and (b) time-dependent effects of nintedanib on STAT3-related protein levels. Cells were treated with nintedanib at the indicated doses and times. Whole-cell extracts were analyzed by western blot analysis using anti-p-STAT3, anti-STAT3, anti-cyclin D1, anti-survivin, anti-Mcl-1, anti-PARP and anti-actin antibodies. Quantification of the protein levels was performed by the ImageJ software. The means of at least three independent experiments performed in triplicate are shown. *P<0.05; **P<0.01; ***P<0.001. The data are shown as the mean ± s.d.
abolished nintedanib-mediated cell death (Figure 3b and c). In addition, nintedanib treatment significantly increased SHP-1 activity in MDA-MB-468 cells (Figure 3d, upper panel). As expected, PTPRD was decreased in nintedanib-treated TNBC cells (Figure 3d, lower panel).

Previous studies have indicated that the autoinhibitory structure of the N-SH2 and PTP domains is the major regulator of SHP-1 activity. Therefore, we used two mutant SHP-1 constructs to mimic the open-form structure of SHP-1 and examine the effect of nintedanib on SHP-1 autoinhibition. TNBC cells transduced with ΔN1 and D61A mutant SHP-1-expressing vectors were insensitive to nintedanib-mediated STAT3 inhibition (Figure 3e). We also found that cells ectopically expressing mutant SHP-1 had much lower endogenous p-STAT3 levels compared to control cells (Figure 3e, lower). Therefore, nintedanib potentiates SHP-1...
Nintedanib diminishes xenograft tumor growth of TNBC cells. Mice were orally administered nintedanib (30 mg kg$^{-1}$ body weight) three times a week as described in the Methods section. Control mice received vehicle. (a) Growth curves, (b) tumor weight and (c) body weight of xenograft mice bearing MDA-MB-231 tumors ($n=6$). The data are shown as the mean ± s.e. (d) The protein levels of p-STAT3, STAT3 and PARP as assessed by western blot analysis in MDA-MB-231 tumors. (e) SHP-1 activity in MDA-MB-231 tumors ($n=6$). The data are shown as the mean ± s.d. (f) H&E and IHC staining for p-STAT3 and the apoptosis index based on TUNEL staining in mice with MDA-MB-231 xenograft tumors and administered either vehicle or nintedanib ($\times200$).
activity by relieving its autoinhibitory conformation to suppress p-STAT3 levels.

Nintedanib suppresses xenograft tumor growth of TNBC cells via SHP-1/STAT3 signaling

To validate the effect of nintedanib on the tumor growth of TNBC cells, nude mice bearing MDA-MB-231 tumors were orally administered either nintedanib or vehicle to assess the growth of the xenografted tumors. The average tumor size (Figure 4a) and tumor weight (Figure 4b) were reduced in mice administered nintedanib. However, there were no differences in body weight between the drug-treated mice and the control mice (Figure 4c). Moreover, we investigated whether nintedanib-mediated inhibition of tumor growth in MDA-MB-231 cells was dependent on the SHP-1/p-STAT3 pathway. The data showed that p-STAT3 protein levels were reduced (Figure 4d), whereas cleaved PARP levels (Figure 4d) and SHP-1 activity were increased (Figure 4e) in the tumor samples from mice treated with nintedanib. Notably, the downregulation of p-STAT3 was also accompanied by elevated TUNEL staining in vivo (Figure 4f). Taken together, these data indicate that nintedanib inhibits TNBC tumor growth via SHP-1/p-STAT3 signaling.

SHP-1 levels are downregulated whereas p-STAT3 protein levels are upregulated in tumor samples, and SHP-1 transcripts are associated with better disease-free survival in patients with TNBC

To assess whether any significant differences in SHP-1 and p-STAT3 expression exist in TNBC carcinoma specimens compared with normal tissues, IHC data were analyzed. We evaluated the SHP-1 and p-STAT3 protein levels in patients with TNBC. The levels of SHP-1 were downregulated in the tumor samples (Figure 5a, left panel), whereas the levels of p-STAT3 were upregulated (Figure 5a, right panel). Furthermore, the relationship between SHP-1 and p-STAT3 in tumor tissues from patients with TNBC were analyzed using the Pearson correlation analysis. The relative expression of SHP-1 was inversely correlated with the protein levels of p-STAT3 in TNBC specimens (Figure 5b). The survival analysis
from the Kaplan–Meier plotter online data set of TNBC cases demonstrated that higher levels of SHP-1 transcripts were associated with better disease-free survival in patients with breast cancer (Figure 5c, right panel), especially among TNBC patients (Figure 5c, left panel).

**DISCUSSION**

TNBC tends to behave more aggressively and have a higher risk of distant recurrence than other subtypes of breast cancer. Due to a lack of established therapeutic targets, it is difficult to develop new targeted drugs for TNBC. STAT3 activation has been linked to multiple malignant tumors, including breast, ovarian, head and neck, prostate, pancreas and brain cancers. STAT3 is highly expressed and activated in most breast cancers, especially TNBC. High levels of p-STAT3 are correlated with worse outcomes in patients with invasive breast cancers. In this study, we found that the SHP-1 levels were downregulated in most tumors and correlated with higher levels of p-STAT3 expression. In addition, we searched the Kaplan–Meier plotter online database and found that the SHP-1 transcript levels correlate with better relapse-free survival among TNBC patients (Figure 5). Apparently, the SHP-1/p-STAT3 signaling axis might be a potential therapeutic target as well as a clinical prognostic indicator in patients with TNBC.

Our findings that nintedanib regulates the STAT3 pathway provide a rationale for its use to treat TNBC. We found that nintedanib was effective in blocking STAT3 activation, thus leading to the suppression of numerous proteins involved in cancer survival and proliferation (Figure 2). Here we found evidence that STAT3 inhibition is linked to nintedanib-induced SHP-1 activation in both in vitro experiments and a preclinical TNBC xenograft tumor model (Figures 3d and 4e). Blocking SHP-1 diminished the nintedanib-inhibited STAT3 effect, which provided further evidence that SHP-1 is the key modulator in nintedanib-mediated STAT3 inhibition (Figure 3). We also found that nintedanib did not further increase SHP-1 activity in cells expressing SHP-1 mutant clones and that these cells were insensitive to nintedanib-mediated p-STAT3 inhibition (Figure 3), suggesting that nintedanib restrains STAT3 activation by regulating SHP-1 autoinhibition. Therefore, the SHP-1/p-STAT3 pathway could be a crucial target for predicting the response to nintedanib.

Various PTPs have been reported to regulate the STAT3 pathway, including SHP-1, SHP-2 and PTEN. However, as shown in Supplementary Figure 4, nintedanib treatment had no obvious effect on either PTEN or SHP-2 but suppressed the phosphorylation of JAK2 (Tyr1007/1008) and Src (Tyr 416). SHP-1 is known to directly bind to JAK2 kinase to induce its dephosphorylation and inhibition. It is possible that nintedanib decreased the p-JAK2 levels by increasing the SHP-1 activity. Alternatively, nintedanib is a multitargeted angiokinase inhibitor against PDGFR, FGFR, VEGFR and non-receptor tyrosine kinases such as Src. Since PDGFrβ has been reported to induce the JAK2–STAT3 pathway by activating Src, nintedanib might inhibit JAK2 by directly inhibiting PDGFrβ and Src.
Several lines of evidence have revealed that nintedanib exerts effective antitumor activities in many human tumor xenograft models, including NSCLC, HCC, renal cell carcinoma, colon cancer, ovarian cancer, pancreatic ductal adenocarcinoma and prostate cancer.\textsuperscript{15,37–39} Nintedanib was also observed to strengthen the antitumor response of standard chemotherapeutic drugs. Our previous study demonstrated that nintedanib-induced apoptosis of hepatocellular carcinoma cells is independent of its anti-angiokinase activity via the SHP-1/p-STAT3 pathway.\textsuperscript{38}

There have been various strategies targeting oncogenic STAT3 activity that use many designated agents or natural compounds (for example, JAK inhibitors) or small molecules that directly block functional STAT3 dimerization (via SH2 domains).\textsuperscript{40,41} The approach of enhancing SHP-1, a negative regulator of STAT3 phosphorylation, provides an alternative method independent of JAK inhibition. We previously identified that the multi-angiokinase inhibitor sorafenib can act as a direct enhancer of SHP-1, which proves the concept of the SHP-1/p-STAT3 strategy.\textsuperscript{42,43} This was further supported by our finding that regorafenib, whose chemical structure is highly similar to that of sorafenib and differs only by a fluoro substitution on the sorafenib moiety,\textsuperscript{44} can also directly enhance SHP-1 activity.\textsuperscript{43} Accordingly, we generated a series of sorafenib derivatives that are devoid of the angiokinase (VEGFR/PDGFR) inhibitory activity and classified them as SHP-1 agonists.\textsuperscript{45} We have shown that the direct SHP-1 agonist SC-43 is effective in TNBC cells.\textsuperscript{18} In addition to nintedanib, SHP-1 enhancers that have been preclinically examined include sorafenib analogues (SC agents such as SC-1, SC-49, SC-60, SC-78 and SC-43) as well as dovitinib and obatoclax analogues such as SC-2001.\textsuperscript{19,46–50} Interestingly, the chemical structure of nintedanib is different from both sorafenib and regorafenib as well as the sorafenib derivatives, and future structural studies on the crystallization of SHP-1/agonist complexes may help delineate the detailed interactions between these agents and SHP-1.

In conclusion, we demonstrated that nintedanib activated SHP-1 by directly relieving the autoinhibition of SHP-1 and significantly inducing TNBC cell apoptosis via SHP-1-dependent p-STAT3 inhibition (Figure 6). Our findings provide a greater understanding of the molecular mechanism of nintedanib-driven regulation and identify the SHP-1/p-STAT3 pathway as a predictor of the nintedanib response, which can maximize the clinical benefits for TNBC treatment. However, future studies to elucidate the mechanism by which nintedanib inhibits p-STAT3 signaling via the disruption of SHP-1 autoinhibition may lead to further progress in a new targeted therapy for TNBC.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**

This work was supported by grants from the Taiwan Clinical Oncology Research Foundation; the Yen Tjing Ling Medical Foundation (CI-104-07); the Ministry of Science and Technology, Taiwan (MOST 103-2325-B-075-002, MOST 104-2628-B-075-001-MY3, 105-2314-B-002-190-MY2); the National Health Research Institutes, Taiwan (NHRI-EX106-10608BI); Yang-Ming Branch of Taipei City Hospital (10601-62-020); Taipei Veterans General Hospital (V104C-151, V105C-067, V106C-101); the TVGH-NTUH Joint Research Program (VN105-09 and VN106-07); the Taipei Veterans General Hospital and National Taiwan-University Hospital, and the Ministry of Health and Welfare, Executive Yuan, Taiwan (MOHW105-TDU-B-211-134003 and MOHW106-TDU-B-211-144-003 for the Center of Excellence for Cancer Research at Taipei Veterans General Hospital). This study was also partially supported by the Chong Hsin Loon Memorial Cancer and the Biotherapy Research Center of National Yang-Ming University, Taipei, Taiwan.

**Author contributions:** LMT and KFC are the corresponding authors and were responsible for coordinating and editing the manuscript. CYL and TTH drafted the manuscript. CTH, CYL, CHL, KYL, WCT and TIC conducted the in vitro experiments. PYC, WLW, MHC and CHL conducted the animal experiments. CYL, TTH, CWS, LMT and KFC helped with data interpretation and statistical analysis. CYL, TTH, PYC, CTH, CHL, WLW, KYL, WCT, JCS and MHC prepared the figures. All authors made substantial contributions to either the conception or design of the work. All authors have read, critically revised for intellectual content, and approved the final manuscript. All authors agreed on the accuracy and integrity of all parts of the work.

1 Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y \textit{et al.} Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. \textit{J Clin Invest} 2011; 121: 2756–2767.

2 Mayer IA, Abramson VG, Lehmann BD, Pieterpol JA. New strategies for triple-negative breast cancer—deciphering the heterogeneity. \textit{Cancer Clin Res} 2014; 20: 782–790.

3 Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW. SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. \textit{J Cell Biochem} 2003; 90: 1026–1037.

4 Lopez-Ruiz P, Rodriguez-Urrea J, Cariaga AE, Cortes MA, Colas B. SHP-1 in cell-cycle regulation. \textit{Anticancer Agents Med Chem} 2011; 11: 89–98.

5 Yang J, Liu L, He D, Song X, Liang X, Zhao ZJ \textit{et al.} Crystal structure of human protein-tyrosine phosphatase SHP-1. \textit{J Biol Chem} 2003; 278: 6516–6520.

6 Tauchi T, Ohayashi K, Yamashita Y, Sugimoto S, Toyama K. SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. \textit{Int J Oncol} 1997; 11: 471–475.

7 Bousquet C, Delesque N, Lopez F, Saint-Laurent N, Estève JP, Bedecès K \textit{et al.} sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. \textit{J Biol Chem} 1998; 273: 7099–7106.

8 Cuevas B, Lu Y, Watt S, Kumar R, Zhang J, Siminovitch KA \textit{et al.} SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. \textit{J Biol Chem} 1999; 274: 27583–27589.

9 Vitale G, Zappavigna S, Marra M, Dictore A, Meschini S, Condello M \textit{et al.} The PPAR-gamma agonist troglitazone antagonizes survival pathways induced by SHP-3 in recombinant interferon-beta treated pancreatic cancer cells. \textit{Biotechnol Adv} 2012; 30: 169–184.

10 Abubaker K, Luwor RB, Escalona R, McNally O, Quinn MA, Thompson EW \textit{et al.} Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of pacilitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. \textit{Front Oncol} 2014; 4: 75.

11 Kim SR, See HS, Choi HS, Cho SG, Kim YK, Hong EH \textit{et al.} Trichosanthes kirilowii ethanol extract and cucurbitacin D inhibit cell growth and induce apoptosis through inhibition of STAT3 activity in breast cancer cells. \textit{Evid Based Complement Alternat Med} 2013; 2013: 975350.

12 Walker SR, Xiang M, Frank DA. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. \textit{Mol Endocrinol} 2014; 382: 616–621.
